Assessment of Hemostasis after Plasma Exchange Using Rotational Thrombelastometry (ROTEM) by Thölking, G.B. (Gerold) et al.
RESEARCH ARTICLE
Assessment of Hemostasis after Plasma
Exchange Using Rotational
Thrombelastometry (ROTEM)
Gerold Thölking1*, Rolf Mesters2, Ralf Dittrich3, Hermann Pavenstädt1, Philipp Kümpers1,
Stefan Reuter1
1 Department of Medicine D, Division of General Internal Medicine, Nephrology and Rheumatology,
University Hospital of Münster, Albert-Schweitzer-Campus 1, Münster, 48149, Germany, 2 Department of
Medicine A, Division of Hematology and Oncology, University Hospital of Münster, Albert-Schweitzer-
Campus 1, Münster, 48149, Germany, 3 Department of Neurology, University Hospital of Münster, Albert-
Schweitzer-Campus 1, Münster, 48149, Germany
* Gerold.Thoelking@ukmuenster.de
Abstract
Background
Therapeutic plasma exchange (TPE)-based protocols immediately before cadaveric donor
kidney transplantation have been extensively used in highly sensitized recipients. Plasma
is generally preferred over human albumin as replacement fluid to avoid depletion of coagu-
lation factors and perioperative bleeding. The aim of this study was to estimate bleeding risk
after TPE replaced with albumin using rotational thromboelastography (ROTEM).
Methodology
Ten patients without overt coagulation abnormalities underwent TPE. Standard laboratory
coagulation tests (thromboplastin time, activated partial thromboplastin time (aPTT), inter-
national normalized ratio (INR), thrombin clotting time, fibrinogen levels and antithrombin
activity) were compared with thrombelastometry analysis (EXTEM and INTEM tests) before
and after TPE.
Principal Findings
TPE significantly reduced fibrinogen levels (482 ± 182 vs. 223 ± 122 mg/dL), antithrombin
activity (103 ± 11 vs. 54 ± 11 %), and prolonged aPTT (28 ± 3 vs. 45 ± 8 s), thromboplastin
time (108 ± 11 vs. 68 ± 11 %), INR (0.95 ± 0.06 vs. 1.25 ± 0.16), and thrombin clotting time
(18 ± 2 vs. 20 ± 3 s). INTEM and EXTEM analyses revealed significantly prolonged clot-for-
mation time and reduced maximum clot firmness.
Conclusions/Significance
TPE replaced with albumin induces significant changes in global hemostasis parameters
thus potentially increasing bleeding risk. Therefore, pretransplant TPE should be consid-
ered carefully in indicated patients before kidney transplantation. The role of the ROTEM
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point-of-care test to estimate the risk of bleeding in renal transplantation needs to be evalu-
ated in further studies.
Introduction
Therapeutic plasma exchange (TPE) is used as a rescue therapy for antibody-mediated diseases
but causes far more effects than simple antibody depletion [1, 2]. Mainly in the USA and
Japan, TPE is a standard procedure in desensitization of patients before ABO incompatible
(ABOi) renal transplantation (RTx) [3, 4]. It is also employed for depletion of antibodies in
high-risk sensitized patients immediately before RTx [5]. In general, two different kinds of
replacement solutions exist [6]. In most cases, use of human serum albumin solution (5%) in
saline is preferred due to better safety and side-effect profile although this leads to a depletion
of most plasma proteins, especially when repeatedly applied. Albumin preparations are pro-
cessed for convenient use (easy handling and storage, decreased need for IV calcium), virus
inactivation and are well tolerated by most patients [7–9]. Plasma handling is more complex
(blood type specific ordering, thawing, greater frequency of hypocalcemia due to citrate antico-
agulant in the plasma) and is more likely to cause allergic reactions. However, because plasma
replaces all plasma proteins it is potentially the solution of choice in the perioperative manage-
ment of the kidney transplant recipient to avoid removal of clotting factors and subsequent
increased bleeding risk [10].
Besides its effects on clotting factors, cellular blood components i.e. platelets are also influ-
enced by TPE [11, 12]. In the case of RTx patients, TPE causes changes in an already pro-
foundly changed coagulation system of patients with renal failure [13]. Thus, perioperative
bleeding management and monitoring of coagulation activity of RTx recipients is challenging
and evaluation of standard test like activated Partial Thromboplastin Time (aPTT), Prothrom-
bin Time (PT, Quick)/International Normalized Ratio (INR) might be inferior to point-of-care
(POC) assays that evaluate the viscoelastic properties of blood i.e. including thrombelastogra-
phy and rotational thromboelastometry (ROTEM) [14]. These tests can assess the whole clot-
ting process at the bedside. Coagulation is tested in whole blood, and includes interactions with
platelets and red cells, thereby providing additional information on patient`s coagulation status
to estimate patient`s bleeding risk more precisely [15]. In fact, if ROTEM analysis is unremark-
able, one should seek for surgical bleedings.
As aforementioned, the usage of albumin for TPE in sensitized patients receiving cadaveric
RTx immediately before surgery would have several advantages compared to plasma use. How-
ever, due to possible changes on global hemostasis, it`s effects need to be evaluated in this
regard. Thus, we herein evaluate the effect of TPE with albumin on coagulation by standard
coagulation tests and ROTEM analysis.
Material and Methods
Study population
From 2011 to 2013 ten patients underwent TPE treatment due to neurologic indications in our
center. Clinical data were collected prior to first TPE. Data of all patients were anonymized and
de-identified prior to analysis. Our study was performed in accordance with the declaration of
Helsinki and approved by the local ethics committee (Ethik Kommission der Ärtzekammer
Westfalen-Lippe und der Medizinischen Fakultät der Westfälischen Wilhelms-Universität, No.
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2011-601-f-S). Enrollment was performed after written informed consent was given by all par-
ticipants prior to first TPE for recording their clinical data and use in anonymized analysis.
Therapeutic plasma exchange (TPE)
According to the standard protocol of our center, prior to first TPE, a central venous dialysis
catheter was inserted into the internal jugular vein. TPE was performed using a COM.TEC cell
separator (Fresenius Hemo-Care GmbH, Bad Homburg, Germany). All patients were treated
five times with 2L albumin 5% (0.4 to 1.0 plasma volumes) per session using an interval of 1–2
days. In contrast to regimes of other groups, we did not use (additional) fresh frozen plasma in
our patients. Blood flow rates were 50–70 mL per min. All patients underwent regional pre-
centrifugal anticoagulation with citrate (ACD-A, Hemonetics, Hemonetics corporation, Brain-
tree, Massachusetts, USA, 1:20 ml/min in relation to blood flow) followed by post-centrifugal
calcium (Calcium gluconate 10%, B. Braun Melsungen AG, Melsungen, Germany) application
(started with 15 mL per h and adaption to clinical symptoms of the patients).
Laboratory tests
Ethylenediaminetetraacetic acid (EDTA) and citrated blood samples were obtained immedi-
ately before and after the first procedure from the central venous catheter. Blood count was car-
ried out from EDTA blood and included red blood cells, hemoglobin (Hb), hematocrit, white
blood count (WBC) and platelets. Conventional coagulation parameters comprised fibrinogen,
aPTT, INR, antithrombin (AT) and thrombin time (TT).
ROTEM thrombelastographic analysis
All samples were analyzed within 90 min after collection using a ROTEM Coagulation Ana-
lyzer according to the manufacturer’s protocol (Pentapharm, Munich, Germany). EXTEM (tis-
sue factor activation) and INTEM (ellagic acid/phospholipid activation) were performed.
The following ROTEM parameters were analyzed: clot-formation time (CFT), maximum
clot firmness (MCF), and clotting time (CT). CT is the latency time from adding the reagent to
blood until initiation of clotting. CT is influenced by activities of conventional coagulation fac-
tors. CFT is the time from initiation of clotting until a clot firmness of 20 mm has been reached.
CFT is also influenced by activities of coagulation factors but also includes platelet count/func-
tion, thrombin formation, fibrin precipitation, fibrinogen and hematocrit. MCF represents
absolute strength of the fibrin and platelet clot. MCF is affected by fibrin and fibrinogen con-
centration, platelet count/function, thrombin concentration, factor XIII, and hematocrit. Fig 1
illustrates the parameters in a thrombelastogram obtained by ROTEM.
Statistical analysis
Statistical analyses of data and figure preparation were performed using GraphPad Prism 4.0
(GraphPad Software, La Jolla, CA, USA).
The Wilcoxon signed rank test was used for all blood values and coagulation parameters.
All tests were two-sided and P-values were considered significant if<0.05.
Results
Patient characteristics
Descriptive statistics of the patients who underwent TPE with albumin are presented in
Table 1. The patient cohort consisted of 6 male and 4 female Caucasian patients with a median
age of 52.4 (range 21.7–62.7) years. 0.4 to 1.0 plasma volumes were processed during each
Hemostasis after Plasma Exchange
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session. Mean exchanged plasma volume was 27.0±5.2 mL/kg BW (range 16.4–33.9 mL/kg
BW). No serious adverse events due to TPE or during the entire hospital stay were observed.
Laboratory parameters before first TPE
The conventional coagulation parameters, the blood count and ROTEM analysis are shown in
Table 2. Prior to TPE all assessed parameters were within the normal range except fibrinogen,
which showed an increased mean value of 482±182 mg/dL.
Fig 1. Thrombelastogram obtained by rotational thromboelastography (ROTEM). ROTEM analysis is a point-of-care assay that allows the assessment
of the complete clotting process. Functional coagulation parameters like clot-formation time (CFT), maximum clot firmness (MCF), and clotting time (CT) are
tested in whole blood.
doi:10.1371/journal.pone.0130402.g001
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Effect of TPE on coagulation parameters
Immediately after TPE, significant decreased values were obtained in erythrocytes (-2%),
hemoglobin (-5%), hematocrit (-6%) and platelets (-11%) while white blood count showed an
increase (+6%, not significant). Most coagulation parameters changed as hypothesized. Fibrin-
ogen concentration (482 ± 182 vs. 223 ± 122 mg/dL; -54%), antithrombin activity (103 ± 11 vs.
54 ± 11%; -48%), and PT/Quick (108 ± 11 vs. 68 ± 11%; -37%) significantly dropped. Further,
aPTT (28 ± 3 vs. 45 ± 8 s; +60%), INR (0.95±0.06 vs. 1.25±0.16; +32%), and TT (18 ± vs. 20 ± 3
s; +11%) changed significantly (Table 2, Fig 2). INTEM analysis revealed significantly pro-
longed CFT (68 ± 26 vs. 97 ± 50 s; +43%) and reduced maximumMCF (66 ± 8 vs. 58 ± 11 mm;
Table 1. Patient characteristics.
Age (yr) 52.4 (21.7–62.7)
Gender (m/f) 6/4
Weight (kg) 72 (55–122)
Height (m) 1.73 ± 0.12
BMI (kg/m2) 24 (20–38)
Neurological disorder
Multiple sclerosis 3
Guillain-Barré syndrome 2
Limbic encephalitis 2
Neuromyotonia 1
Myasthenia gravis 2
doi:10.1371/journal.pone.0130402.t001
Table 2. Coagulation parameters, ROTEM analysis and blood count.
before TPE after TPE Δ before and after TPE (%) p-value laboratory range (m/f)
Fibrinogen (mg/dL) 482±58 223±38 -54 0.002 180–350
Antithrombin activity (%) 103±11 54 ± 11 -48 0.0059 70–130
aPTT (s) 28±3 45±8 +60 0.0059 24–36
PT (%) 108±11 68±11 -37 0.002 80–120
INR 0.95±0.06 1.25±0.16 +32 0.0039 0.85–1.15
TT (s) 18±2 20±3 +11 <0.014 14–21
INTEM
CFT (s) 68±26 97±50 +43 0.0144 30–110
MCF (mm) 66±8 58±11 -12 0.0057 50–72
CT (s) 168 (127–292) 172 (135–299) +2 0.106 100–240
EXTEM
CFT (s) 79±28 134±55 +70 0.002 34–159
MCF (mm) 67±8 57±10 -15 0.0058 50–72
CT (s) 49 (4–64) 52 (2–74) +6 0.634 38–79
Erythrocytes (x1012/L) 4.1±0.7 4.0±0.7 -2 0.0142 3.92–5.08/4.44–5.61
Hemoglobin (g/dl) 12.3±2.1 11.7±2.0 -5 0.0125 11.9–14.6/13.5–16.9
Hematocrit (%) 36.9±5.5 34.6±5.5 -6 0.0039 36.6–44.0/40.0–49.4
WBC (x109/L) 8.2±3.0 8.7±2.9 +6 0.160 4.49–12.68/3.91–10.9
Platelets (x109/L) 286±102 255±89 -11 0.0039 173-390/166-308
P-values are from the Wilcoxon signed rank test; aPTT, activated prothrombin time; PT, thromboplastin time; INR, international normalized ratio; TT,
thrombin time; CFT, clot-formation time; MCF, maximum clot ﬁrmness; CT, coagulation time; WBC, white blood count.
doi:10.1371/journal.pone.0130402.t002
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-12%). Similarly, significantly prolonged CFT (79 ± 28 vs. 134 ± 55 s; +70%) and reduced MCF
(67 ± 8 vs. 57 ± 10 mm; -15%) were obtained in EXTEM analysis. Neither INTEM nor EXTEM
revealed differences in CT (168 (127–292) vs. 172 (135–299) s (+2%) and 49 (4–64) vs. 52 (2–
74) s (+6%), respectively (Table 2, Figs 3 and 4).
To sum up, all conventional coagulation parameters changed and showed limited blood
coagulation. ROTEM (INTEM and EXTEM) revealed that initiation of clotting remained unaf-
fected while clot formation and firmness are impaired.
Discussion
Although time-consuming and not evidence-based, fresh frozen plasma is generally preferred
over albumin as replacement fluid for TPE immediately before kidney transplantation. Hemor-
heologic changes after TPE do not differ between both replacement strategies, but in contrast
to albumin, plasma replacement avoids depletion of coagulation factors and should therefore
minimize the risk of perioperative bleeding [16, 17]. We herein aimed to provide evidence in
this regard and estimated the bleeding risk after a TPE using standard coagulation parameters
as well as ROTEM POC analysis.
Fig 2. Conventional coagulation factors and platelets before and after therapeutic plasma exchange (TPE) with albumin. After TPE, aPTT
(P = 0.0059), fibrinogen (P = 0.002), antithrombin (P = 0.0059) and platelets (P = 0.0039) showed significant changes.
doi:10.1371/journal.pone.0130402.g002
Hemostasis after Plasma Exchange
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Except an increased fibrinogen concentration, all assessed coagulation parameters were
within the normal range in our study population. Fibrinogen increase was mostly due to acute
phase response in neuronal inflammation [18]. The fibrinogen level is also elevated in patients
suffering from renal insufficiency [19]. Interestingly, this did not translate into a procoagula-
tory state, but in contrast increased the patients`bleeding risk by inhibition of platelet activa-
tion [20]. However, after TPE, fibrinogen concentration dropped. This is well known and some
authors propose to monitor fibrinogen and recommend a switch to plasma when levels fall
below 1.25 g/L [21–25]. In our study TPE led to a 54% reduction of fibrinogen concentration
but in the end fibrinogen remained in the normal range. In addition, we observed significant
changes in many others coagulation parameters. Conventional coagulation test showed that
PT/Quick dropped. In congruence INR increased and aPTT as well as TT prolonged. However,
in our setting using 0.4–1.0 plasma volumes albumin for replacement per session assessed
effects are moderate. In cases of higher volume exchanges, aPTT and PT change more dramati-
cally [21]. Thus, TPE with albumin resulted in a significant loss of coagulation factors. Loss can
be attributed to removal and to a small proportion to activation by the TPE process. We used
Fig 3. INTEM and EXTEM analyses before and after therapeutic plasma exchange (TPE) with albumin.
The thrombelastogram appears elongated and in a narrow shape after TPE. These differences correlate to
significant changes in clot-formation time (CFT) and maximum clot firmness (MCF).
doi:10.1371/journal.pone.0130402.g003
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centrifugal cell separation in order to minimize possible coagulation activation by hollow fiber
plasma filters [26]. Moreover, in the preoperative setting, one would prefer regional anticoagu-
lation with citrate (usually used for centrifugal TPE) over systemic heparin application as used
for hollow fiber filtration [22]. Recovery of coagulation parameters takes time e.g. 24h for
aPTT and PT and 48–72h for fibrinogen [27]. This is probably of high importance as per se the
risk of major bleeding in renal patients is increased [28]. Notably, overall the postoperative
hemorrhage rate after kidney transplantation is relevant [29, 30]. Platelets also had been signifi-
cantly reduced by TPE. Unfortunately, we do not know by simple platelet count analysis if the
contact with the TPE equipment affects their function which has been shown previously nor if
there are differences in regards to platelet function when comparing TPE with albumin to TPE
with fresh frozen plasma [31, 32]. As if matters are not already complicated enough, anticoagu-
latory factors are also depleted by TPE. We observed a significant, 50% reduction of antithrom-
bin activity after TPE. As antithrombin serves as an indicator substance, one can assume that
other factors like protein S or C are depleted as well [23, 24, 33]. Although rare, renal venous
thrombosis necessitating transplant nephrectomy is a serious complication [34]. Thus, unfrac-
tioned heparin is commonly administered for the perioperative management of renal trans-
plant patients. In this context, reduction of antithrombin might be relevant especially when
aPTT is used to adjust the antithrombotic therapy [30, 35].
Fig 4. Clot-formation time (CFT) andmaximum clot firmness (MCF) of all patients before and after TPE. INTEM and EXTEM analyses revealed a
significant prolonged CFT (P = 0.0144 and P = 0.002, respectively) and reduced MCF (P = 0.0057 and P = 0.0058, respectively).
doi:10.1371/journal.pone.0130402.g004
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However, bleeding risk prediction in a kidney recipient is difficult and studies linking sin-
gle coagulation parameters and perioperative bleeding in kidney transplantation have not
been performed. As we are confronted with the disturbance of multiple coagulation parame-
ters after TPE, one should consider performing tests which include a functional analysis of
the whole clotting process, especially, when the additional loss of anticoagulatory factors
complicates the situation.
ROTEM analysis can assess the entire clotting process, from initiation and clot formation to
clot stability, at the bedside and therefore allows timely assessment of bleeding risk and man-
agement of hemostatic therapy [15, 36]. ROTEM test is influenced by interactions of platelets
and red cells, thereby providing additional information to simple measurements of single fac-
tors on patient`s coagulation status. This should probably lead to a more precise estimation of
patient`s bleeding risk. As it can be rapidly performed, it might be useful in order to keep graft
ischemia time short when one needs to wait for time consuming standard coagulation test after
TPE to perform RTx. Therefore, we had chosen to compare standard coagulation parameters
to ROTEM for assessment of clotting before and after TPE with albumin. ROTEM has already
been shown to effectively detect thrombocytopenia and hypofibrinogenemia in hypocoagulable
patients undergoing orthotopic liver transplantation [37–39]. However, if the performance of
ROTEM can efficiently reduce blood loss or transfusion need during liver transplantation has
to be questioned [37].
In our study, analyses had been performed with extrinsically activated EXTEM assay and
intrinsically activated INTEM test [36]. Both tests revealed significantly prolonged CFT after
TPE with albumin. MCF, which usually shows an inverse correlation to CFT, was significantly
reduced [36]. Notably, CT did not change significantly and is therefore not sufficiently sensi-
tive to estimate bleeding risk after TPE with albumin. Thus, TPE did not significantly alter the
initiation of clotting but leads to a distinct reduction of clot formation (CFT) and strength
(MCF). This is related to fibrinogen reduction by TPE.
In our study, 2 L albumin 5% (0.4 to 1.0 plasma volumes) were used per TPE session. This
procedure displayed the standard method of our center until 2013. Compared to the literature,
the replaced albumin volume in our study is within the lower range. Therefore, we have
changed our standard protocol in late 2013 according to the guidelines on the use of therapeu-
tic apheresis in clinical practice [40].
Due to the standard protocol of our center, central lines were placed in all patients before
TPE. Nevertheless, several studies describe increased complications rates with central lines in
this setting [41, 42]. As a less invasive alternative, successful TPE with peripheral venous access
was demonstrated even in neurology patients [42, 43]. Central lines offer a continuous high
blood flow rate and a straight workflow in the clinical setting. From our experience, the use of
central venous catheters is a safe method in the hand of practiced physicians in our clinical set-
ting. In patients before RTx existing arteriovenous fistulae can be used.
Limitations
This study has limitations. First, it is a small single-center study of patients with neurologic dis-
ease which do not reflect the complete complexity of coagulation disturbances of renal patients.
Second, the ROTEM-based coagulation testing has not been evaluated for RTx yet. Third, we
did not assess clinically meaningful endpoints like postoperative bleeding episodes as we
selected a patient population which, for safety reasons, did not undergo surgery after TPE. As
we cannot recommend to perform TPE with albumin prior to RTx in regards to our study
data, one should evaluate ROTEM after TPE using plasma prior to RTx in further studies [44].
Hemostasis after Plasma Exchange
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Conclusion
In summary, we conclude from our data that even TPE with albumin without addition of
plasma is able to cause significant disturbances of blood coagulation due to loss of pro- as well
as anticoagulant factors. As clot formation and firmness are altered, the bleeding risk following
RTx would increase. Thus, in patients needing perioperative TPE, e.g., patients who are immu-
nized or suffer from acute humoral rejection, 100% plasma is recommended as exchange
medium for TPE. Moreover, ROTEM is a rapid and easy to perform POC system that detects
the induced coagulopathy; however CT measurement is not sufficiently sensitive.
Acknowledgments
We acknowledge support by Deutsche Forschungsgemeinschaft and Open Access Publication
Fund of University of Münster.
Author Contributions
Conceived and designed the experiments: GT PK SR. Performed the experiments: GT RM RD.
Analyzed the data: GT SR. Contributed reagents/materials/analysis tools: HP RM. Wrote the
paper: GT HP SR.
References
1. Clark WF (2012) Plasma exchange for renal disease: evidence and use 2011. J Clin Apher 27: 112–
116. doi: 10.1002/jca.21221 PMID: 22535650
2. Reeves HM andWinters JL (2014) The mechanisms of action of plasma exchange. British journal of
haematology 164: 342–351. doi: 10.1111/bjh.12629 PMID: 24172059
3. Montgomery RA, Locke JE, King KE, Segev DL, Warren DS, Kraus ES, et al. (2009) ABO incompatible
renal transplantation: a paradigm ready for broad implementation. Transplantation 87: 1246–1255. doi:
10.1097/TP.0b013e31819f2024 PMID: 19384174
4. Takahashi K, Saito K, Takahara S, Okuyama A, Tanabe K, Toma H, et al. (2004) Excellent long-term
outcome of ABO-incompatible living donor kidney transplantation in Japan. American journal of trans-
plantation: official journal of the American Society of Transplantation and the American Society of
Transplant Surgeons 4: 1089–1096.
5. Morath C, Beimler J, Opelz G, Ovens J, Scherer S, Schmidt J, et al. (2010) An integrative approach for
the transplantation of high-risk sensitized patients. Transplantation 90: 645–653. doi: 10.1097/TP.
0b013e3181ea3985 PMID: 20671598
6. McLeod BC (2012) Plasma and plasma derivatives in therapeutic plasmapheresis. Transfusion 52
Suppl 1: 38S–44S. doi: 10.1111/j.1537-2995.2012.03623.x PMID: 22578370
7. Pusey C, Dash C, Garrett M, Gascoigne E, Gesinde M, Gillanders K, et al. (2010) Experience of using
human albumin solution 4.5% in 1195 therapeutic plasma exchange procedures. Transfusion medicine
20: 244–249. doi: 10.1111/j.1365-3148.2010.00999.x PMID: 20230532
8. Goss GA andWeinstein R (1999) Pentastarch as partial replacement fluid for therapeutic plasma
exchange: effect on plasma proteins, adverse events during treatment, and serum ionized calcium. J
Clin Apher 14: 114–121. PMID: 10540365
9. Weinstein R (1996) Prevention of citrate reactions during therapeutic plasma exchange by constant
infusion of calcium gluconate with the return fluid. J Clin Apher 11: 204–210. PMID: 8986866
10. Roman PE, DeVore AD andWelsby IJ (2014) Techniques and applications of perioperative therapeutic
plasma exchange. Current opinion in anaesthesiology 27: 57–64. doi: 10.1097/ACO.
0000000000000037 PMID: 24335592
11. McLeod BC, Sniecinski I, Ciavarella D, Owen H, Price TH, Randels MJ, et al. (1999) Frequency of
immediate adverse effects associated with therapeutic apheresis. Transfusion 39: 282–288. PMID:
10204591
12. Domen RE, Kennedy MS, Jones LL and Senhauser DA (1984) Hemostatic imbalances produced by
plasma exchange. Transfusion 24: 336–339. PMID: 6464159
13. Lutz J, Menke J, Sollinger D, Schinzel H and Thurmel K (2014) Haemostasis in chronic kidney disease.
Nephrol Dial Transplant 29: 29–40. doi: 10.1093/ndt/gft209 PMID: 24132242
Hemostasis after Plasma Exchange
PLOS ONE | DOI:10.1371/journal.pone.0130402 June 29, 2015 10 / 12
14. Luddington RJ (2005) Thrombelastography/thromboelastometry. Clinical and laboratory haematology
27: 81–90. PMID: 15784122
15. Ganter MT and Hofer CK (2008) Coagulation monitoring: current techniques and clinical use of visco-
elastic point-of-care coagulation devices. Anesth Analg 106: 1366–1375. doi: 10.1213/ane.
0b013e318168b367 PMID: 18420846
16. Tek I, Arslan O, Arat M, Ayyildiz E, Tol M, Oral M, et al. (2004) Effects of replacement fluids used for
therapeutic plasma exchange on plasma viscosity and plasma oncotic pressure. Transfusion and aphe-
resis science: official journal of the World Apheresis Association: official journal of the European Soci-
ety for Haemapheresis 31: 89–93.
17. Lamboo M, Poland DC, Eikenboom JC, Harvey MS, Groot E, Brand A, et al. (2007) Coagulation param-
eters of thawed fresh-frozen plasma during storage at different temperatures. Transfusion medicine
17: 182–186. PMID: 17561859
18. Ryu JK, Davalos D and Akassoglou K (2009) Fibrinogen signal transduction in the nervous system.
Journal of thrombosis and haemostasis: JTH 7 Suppl 1: 151–154. doi: 10.1111/j.1538-7836.2009.
03438.x PMID: 19630789
19. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al. (2003) Elevations of inflamma-
tory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107: 87–92.
PMID: 12515748
20. Thekkedath UR, Chirananthavat T, Leypoldt JK, Cheung AK and Mohammad SF (2006) Elevated
fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprotein IIb-
IIIa. American journal of hematology 81: 915–926. PMID: 16917914
21. Tek I, Arslan O, Arat M, Ozcan M, Akdag B and Ilhan O (2003) Effects of replacement fluids on coagula-
tion system used for therapeutic plasma exchange. Transfusion and apheresis science: official journal
of theWorld Apheresis Association: official journal of the European Society for Haemapheresis 28: 3–
7.
22. Pusey CD and Levy JB (2012) Plasmapheresis in immunologic renal disease. Blood Purif 33: 190–
198. doi: 10.1159/000334155 PMID: 22269818
23. Orlin JB and Berkman EM (1980) Partial plasma exchange using albumin replacement: removal and
recovery of normal plasma constituents. Blood 56: 1055–1059. PMID: 6159932
24. FlaumMA, Cuneo RA, Appelbaum FR, Deisseroth AB, Engel WK and Gralnick HR (1979) The hemo-
static imbalance of plasma-exchange transfusion. Blood 54: 694–702. PMID: 465736
25. Derksen RH, Schuurman HJ, Meyling FH, Struyvenberg A and Kater L (1984) The efficacy of plasma
exchange in the removal of plasma components. The Journal of laboratory and clinical medicine 104:
346–354. PMID: 6206173
26. Pieroni L, Levi Mortera S, Greco V, Sirolli V, Ronci M, Felaco P, et al. (2015) Biocompatibility assess-
ment of haemodialysis membrane materials by proteomic investigations. Molecular bioSystems.
27. Wood L and Jacobs P (1986) The effect of serial therapeutic plasmapheresis on platelet count, coagu-
lation factors, plasma immunoglobulin, and complement levels. J Clin Apher 3: 124–128. PMID:
3516979
28. Parikh AM, Spencer FA, Lessard D, Emery C, Baylin A, Linkletter C, et al. (2011) Venous thromboem-
bolism in patients with reduced estimated GFR: a population-based perspective. Am J Kidney Dis 58:
746–755. doi: 10.1053/j.ajkd.2011.06.021 PMID: 21872977
29. Hernandez D, Rufino M, Armas S, Gonzalez A, Gutierrez P, Barbero P, et al. (2006) Retrospective
analysis of surgical complications following cadaveric kidney transplantation in the modern transplant
era. Nephrol Dial Transplant 21: 2908–2915. PMID: 16820375
30. Pawlicki J, Cierpka L, Krol R and Ziaja J (2011) Risk factors for early hemorrhagic and thrombotic com-
plications after kidney transplantation. Transplantation proceedings 43: 3013–3017. doi: 10.1016/j.
transproceed.2011.07.018 PMID: 21996213
31. Schoorl M, Schoorl M, Nube MJ and Bartels PC (2013) Coagulation activation, depletion of platelet
granules and endothelial integrity in case of uraemia and haemodialysis treatment. BMC nephrology
14: 72. doi: 10.1186/1471-2369-14-72 PMID: 23537104
32. Feuring M, Gutfleisch A, Ganschow A, Richter E, Eichler H, Dempfle CE, et al. (2001) Impact of plasma-
pheresis on platelet hemostatic capacity in healthy voluntary blood donors detected by the platelet func-
tion analyzer PFA-100. Platelets 12: 236–240. PMID: 11454258
33. Zantek ND, Morgan S, Zantek PF, Mair DC, Bowman RJ and Aysola A (2014) Effect of therapeutic
plasma exchange on coagulation parameters in patients on warfarin. J Clin Apher 29: 75–82. doi: 10.
1002/jca.21294 PMID: 24000079
Hemostasis after Plasma Exchange
PLOS ONE | DOI:10.1371/journal.pone.0130402 June 29, 2015 11 / 12
34. Lempinen M, Stenman J, Kyllonen L and Salmela K (2015) Surgical Complications Following 1670
Consecutive Adult Renal Transplantations: A Single Center Study. Scandinavian journal of surgery:
SJS: official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.
35. Eng M, Brock G, Li X, Chen Y, Ravindra KV, Buell JF, et al. (2011) Perioperative anticoagulation and
antiplatelet therapy in renal transplant: is there an increase in bleeding complication? Clin Transplant
25: 292–296. doi: 10.1111/j.1399-0012.2010.01293.x PMID: 20529097
36. Gorlinger K, Dirkmann D, Solomon C and Hanke AA (2013) Fast interpretation of thromboelastometry
in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability. Br J Anaesth
110: 222–230. doi: 10.1093/bja/aes374 PMID: 23112213
37. Roullet S, Freyburger G, Cruc M, Quinart A, Stecken L, Audy M, et al. (2015) Management of bleeding
and transfusion during liver transplantation before and after the introduction of a rotational thromboelas-
tometry-based algorithm. Liver transplantation: official publication of the American Association for the
Study of Liver Diseases and the International Liver Transplantation Society 21: 169–179.
38. Stancheva A, Spassov L and Tzatchev K (2011) Correlation between rotation thrombelastometry
ROTEM analysis and standard haemostatic parameters during liver transplantation. Clinical laboratory
57: 407–413. PMID: 21755833
39. Roullet S, Pillot J, Freyburger G, Biais M, Quinart A, Rault A, et al. (2010) Rotation thromboelastometry
detects thrombocytopenia and hypofibrinogenaemia during orthotopic liver transplantation. Br J
Anaesth 104: 422–428. doi: 10.1093/bja/aeq022 PMID: 20185519
40. Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. (2013)
Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the
Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 28:
145–284. doi: 10.1002/jca.21276 PMID: 23868759
41. Kaya E, Keklik M, Sencan M, Yilmaz M, Keskin A, Kiki I, et al. (2013) Therapeutic plasma exchange in
patients with neurological diseases: multicenter retrospective analysis. Transfusion and apheresis sci-
ence: official journal of the World Apheresis Association: official journal of the European Society for
Haemapheresis 48: 349–352.
42. Guptill JT, Oakley D, Kuchibhatla M, Guidon AC, Hobson-Webb LD, Massey JM, et al. (2013) A retro-
spective study of complications of therapeutic plasma exchange in myasthenia. Muscle & nerve 47:
170–176.
43. Noseworthy JH, Shumak KH and Vandervoort MK (1989) Long-term use of antecubital veins for plasma
exchange. The Canadian Cooperative Multiple Sclerosis Study Group. Transfusion 29: 610–613.
PMID: 2672434
44. Abel JJ, Rowntree LG and Turner BB (1990) Plasma removal with return of corpuscles (plasmaphaer-
esis). The Journal of Pharmacology and experimental therapeutics Vol. V. No. 6, July, 1914. Transfu-
sion science 11: 166–177. PMID: 10160881
Hemostasis after Plasma Exchange
PLOS ONE | DOI:10.1371/journal.pone.0130402 June 29, 2015 12 / 12
